Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than comprehensive financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary Share ADRs on January 23, 2009, at a price of $34.09 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on January 23, 2009.
- Share Price: The transaction price was $34.09 per ADR.
- Involved Parties: The notification covers Dr. M M Slaoui (18 units), Mr. W C Louv (10 units), and Dr. D Pulman (14 units).
- Plan Details: The transaction relates to the US Retirement Savings Plan, which is notionally held in GSK Ordinary share ADRs.